Watson is an unincorporated community in Los Angeles County, California. Occupying an area of about 8.5 square miles on the west side of Long Beach near Carson, Watson has a population of just under 33,469. The area has been dominated by oil refineries and terminals since at least the 1930s.
Watson, California's history of heavy industry places it in a high risk category for asbestos exposure. Workers exposed to asbestos may be at risk for malignant mesothelioma and other asbestos-related diseases. If you or a loved one were diagnosed with mesothelioma in Watson, you may also benefit from seeking the advice of a mesothelioma attorney.
Asbestos Exposure at Jobsites in Watson
The Mesothelioma Cancer Alliance has compiled information obtained from a number of sources to identify the following jobsites in Watson where asbestos exposure was known to have occurred. These sites are listed below.
- Alameda Stations
- American Chemical Corporation
- Associated Oil
- Atlantic Richfield Oil Company
- California Petroleum Company
- Colley Engineers & Construction Company
- Fiberglas Engineering & Supply Company
- Hancock Chemical Company
- Johns Manville Products Corporation
- Los Angeles Fertilizer
- Marine Engineering & Supply Company
- North American Aircraft
- Petroleum Midway Company
- Ralph M. Parsons Company
- Richfield Oil Corporation
- Shell Oil
- Stauffer Chemical Company
- Tide Water Associated Oil Company
- Witfield Chemical Company
Filing an Asbestos Lawsuit in Watson, California
Don’t lose your rights! If you or a loved one has been diagnosed with mesothelioma and were exposed to asbestos in California, you may be entitled to compensation. You may have limited time to file a claim. If you have been diagnosed with mesothelioma and have a pathology report in hand to support that diagnosis, you are eligible for financial assistance.
Asbestos Related News in California
The Supreme Court of California has issued a ruling that companies can be held accountable for secondary exposure to asbestos in a worker's home.
PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.